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G protein coupled receptors (GPCRs) modulate the majority
of physiological processes through specific intermolecular
interactions with structurally diverse ligands and activation of
differential intracellular signaling. A key issue yet to be resolved
is howGPCRs developed selectivity and diversity of ligand bind-
ing and intracellular signaling during evolution. We have
explored the structural basis of selectivity of naturally occurring
gonadotropin-releasing hormones (GnRHs) from different spe-
cies in the single functional human GnRH receptor. We found
that the highly variable amino acids in position 8 of the naturally
occurring isoforms ofGnRHplay a discriminating role in select-
ing receptor conformational states. The human GnRH receptor
has a higher affinity for the cognate GnRH I but a lower affinity
for GnRH II andGnRHs from other species possessing substitu-
tions for Arg8. The latter were partial agonists in the human
GnRH receptor. Mutation of Asn7.45 in transmembrane domain
(TM) 7 had no effect on GnRH I affinity but specifically
increased affinity for other GnRHs and converted them to full
agonists. Usingmolecularmodeling and site-directedmutagen-
esis, we demonstrated that the highly conserved Asn7.45 makes
intramolecular interactions with a highly conserved Cys6.47 in
TM 6, suggesting that disruption of this intramolecular interac-
tion induces a receptor conformational change which alloster-
ically alters ligand specific binding sites and changes ligand
selectivity and signaling efficacy. These results reveal GnRH
ligand and receptor structural elements for conformational
selection, and support co-evolution of GnRH ligand and recep-
tor conformations.
Gprotein-coupled receptors (GPCRs)2 constitute the largest
family of signaling molecules in the mammalian genome. Over
800 GPCRs have been identified in the human genome (1).
GPCRs bind a variety of structurally diverse ligands ranging
fromphotons, ions, bioamines, lipids, nucleotides, and peptides
to large polypeptide hormones at the extracellular surface.
They activate a number of different intracellular effector pro-
teins including G proteins or non-G proteins which participate
in themajority of physiological processes. About 50%of current
clinical drugs target GPCRs, and these receptors thus remain a
major avenue for future drug development.
The 7-TMGPCRs are presumed to have evolved froma com-
mon ancestor (2), and are thought to share important structural
and functional characteristics (3–5), but have undergone spe-
cialization tomirror the nature of their cognate ligands. It is not
clear, however, howGPCRs developed ligand selectivity to cog-
nate ligands during evolution. We hypothesized that GPCR
binding specificity is not only determined by ligand contact
residues but also by receptor conformations specified by recep-
tor intramolecular interactions. There is also increasing evi-
dence that ligands can selectively stabilize different receptor
active conformations thereby mediating ligand-induced selec-
tive signaling (LiSS) (6–9). Selection of signaling by analogues
clearly has potential for future drug development with novel
activities and reduced side-effects. Hence, delineation of recep-
tor allosteric communication networks which couple selective
ligand structural elements to specific receptor conformational
changes is fundamental to understanding LiSS (10).
Although only one functionalmember of theGnRH receptor
and two isoforms of GnRH ligands (GnRH I and GnRH II) (Fig.
1A) exist in humans, coexistence of multiple types of GnRH
ligands and receptors was identified in themajority of chordate
and vertebrate species (6). The humanGnRH receptor has high
affinity for GnRH I (Fig. 1, A and B) but a 10-fold lower affinity
for GnRH II, which differs by three amino acids (Fig. 1A). In
contrast, the marmoset and macaque type II GnRH receptors
have a high affinity for GnRH II but a much lower affinity for
GnRH I (11). The human type II GnRH receptor has been
silenced by stop codons and frameshift deletions (6, 12), sug-
gesting that the single subtype of the human GnRH receptor
mediates actions of both ligands. The ligand binding sites iden-
tified in the human GnRH receptor for the conserved N- and
C-terminal amino acids of GnRHs (Fig. 1C) are almost fully
conserved among all GnRH receptors (6). This implies that the
evolutionarily variable residues in position 5, 7, and 8 of the
jawed vertebrate GnRHs confer ligand binding and functional
selectivity (6, 13). We have recently revealed that mutations in
the single subtype of the human GnRH receptor remote from
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ligand binding sites have differential effects on the binding
affinity of the two endogenous ligands (10), implying differen-
tial ligand-receptor conformational selections. Herewe present
studies supporting the hypothesis that changes in the GnRH
receptor conformation occurred coincident with amino acid
changes of GnRH ligands, which modify ligand structure/con-
formation, i.e. there was a reciprocal structural/conformational
selection between ligands and receptors during evolution.
Our preliminary screening mutagenesis of putative TM
interacting residues revealed candidates which appeared func-
tionally important for ligand binding and receptor activation
for further studies. Here we report that the highly conserved
Asn7.45 in TM 7 makes intramolecular interactions with a
highly conserved Cys6.47 in TM6which plays an important role
in control of receptor conformational states of the human
GnRH receptor, involved in binding selectivity and signaling
efficacy of GnRH analogues, which differ by only one amino
acid in position 8.
EXPERIMENTAL PROCEDURES
Site-directed Mutagenesis and Receptor Expression—A PCR
method was used to construct mutant receptors of N7.45A,
C6.47A, and C6.47Y. The mutant receptor DNAs cloned into
the pcDNA I expression vector were validated by di-deoxy
sequencing. Wild-type and mutant receptors were transiently
expressed in COS-7 cells by transfection using a Bio-Rad Gene
Pulser at 230V and 960microfarads with 20g of DNA/0.4-cm
cuvette (1  107 cells; 0.7 ml). After transfection, cells were
grown in Dulbecco’s modified Eagle’s medium (DMEM) sup-
plemented with 10% fetal calf serum, antibiotics, and 2 mM
glutamine (complete DMEM) in the absence or presence of 1
M IN3 (a membrane-permeant non-peptide GnRH receptor
antagonist). Cells were washed four times, each wash lasted for
30min,with 2%Me2SO, 0.1%BSA/Hepes/DMEMat 37 °C after
a 48-h incubation. The cells were then incubatedwith complete
DMEM overnight (18 h), and were washed again as above
prior to assaying. This allowed complete removal of IN3 from
pretreated cells before assaying (10).
Ligand Binding—Radioligand binding assays were per-
formed on intact cells 72 h after transfection (10). Transfected
cells in 12-well culture plates were washed as above and then
incubated with 125I-[His5,D-Tyr6]GnRH (100,000 cpm/0.5
ml/well) and various concentrations of unlabeled GnRH
ligands in 0.1% BSA/Hepes/DMEM for 4 h at 4 °C. Nonspecific
binding was determined in the presence of 1 M unlabeled
GnRH I. After incubation, the cells were rapidly washed with 1
ml ice-cold phosphate-buffered saline (pH 7.4) twice and solu-
bilized in 0.5 ml of 0.1 M NaOH. Radioactivity was counted by
-spectrometry. All experiments were performed in triplicate
and repeated at least three times.
PhI Hydrolysis—Assays for ligand stimulation of inositol
phosphate production were previously described (10). Trans-
fected COS-7 cells were seeded onto 12-well plates in the
absence or presence of 1 M concentration of IN3. After 48 h,
IN3 was washed off as above and labeled overnight with 1
Ci/ml myo-D-[3H]inositol in inositol-free DMEM containing
1% dialyzed fetal calf serum. Before conducting PhI assay, the
cells were washed again as above. Cells were then preincubated
with 0.5 ml of buffer A (140 mM NaCl, 20 mM HEPES, 8 mM
glucose, 4 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 1 mg/ml BSA)
containing 10mMLiCl at 37 °C for 30min, followed by addition
of GnRHs for an additional 30 min. The stimulation was termi-
nated by removal of the medium and addition 0.5 ml of 10 mM
FIGURE 1. Structures of GnRHs and the human GnRH receptor. A, primary
structures of GnRH I, GnRH II, and GnRHs from other species with Arg8 substi-
tution. The N-terminal amino acids (pGlu1-His2-Trp3-Ser4) and C-terminal
amino acids (Pro9-Gly10-NH2) of the decapeptide ligands are highly con-
served over 600 million years of the chordate evolution and are important for
ligand binding (see below) and receptor activation (6). B, an NMR structure of
GnRH I (PDB code: 1YY1) showing a II conformation. C, a homology model
of the 7-TM domains of the human GnRH receptor in the inactive state. The
ligand binding residues for GnRH I are labeled in black. pGlu1 is proposed to
interact with Asn5.39; His2 with Asp2.61/Lys3.32; Tyr5 with Tyr6.58; Arg8 with
Asp7.32; and Gly10NH2 with Asn
2.65. These interactions can all be satisfactorily
accommodated when GnRH in the II conformation is docked to the recep-
tor (not shown for clarity) (6, 10). There is no intermolecular interaction
between Tyr8 of GnRH II and Asp7.32 (green) that interacts with Arg8 of GnRH I
(green) (41). The most highly conserved (80 –100%) residues in the 7 TM
domains among rhodopsin-like family of GPCRs are colored blue.
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formic acid. The [3H]inositol phosphates were isolated from
the formic acid extracts using Dowex AG 1-X8 ion exchange
resin and collected with 1 M ammonium formate containing 0.1
M formic acid and quantified by liquid scintillation counting.
Comparative Modeling of the GnRH Receptor andMolecular
Dynamics (MD) Simulations—Initial homology models of the
human GnRH receptor in the inactive or active state were built
on the crystal structures of bovine rhodopsin (14, 15) (PDB
codes 1U19 and 2I37) using a similar method as previously
described (10, 16, 17), with the “MODELLER” module within
DS Modeling (version 1.6, Accelrys, San Diego, CA). Although
there are concerns in regard to the use of the rhodopsin struc-
ture as a template to model other GPCRs due to low sequence
similarities among the rhodopsin-like family of GPCRs,
sequence analysis suggested that GPCRs share a similar
arrangement of the 7-TM domains. This is also because of the
presence of a few, but significantly conserved residues and
motifs in each of the 7-TMdomains (4, 18, 19). The amino acids
possessing 80–100% conservation are Asn1.50, Leu2.46, Asp/
Asn2.50, Cys3.25, Glu/Asp3.49, Arg3.50, Trp4.50, Phe6.44, Trp/
Phe6.48, Pro6.50, Pro7.50, and Tyr7.53 (4, 18) (Fig. 1C). Molecular
modeling of GPCRs has recently been extensively reviewed by
Fanelli and De Benedetti (18) in which they suggest that com-
parativemodeling of the 7-TMbundle of GPCRs using rhodop-
sin structure as a template is likely to produce reliable results.
The use of rhodopsin to comparatively model the mammalian
GnRH receptor has been validated by the authors (6, 10) and
also by independent groups using extensive site-directed
mutagenesis studies and peptide (20, 21) and non-peptide
docking supported by 76 mutations (22). The MODELLER-
generated models with the highest values of the three-dimen-
sional profile score, computed by means of the module of “ver-
ify protein” in the DS modeling, were selected for further
refinement. The models incorporating all previously experi-
mentally identified amino acid interactionswere subjected to in
vacuo energy minimization and MD simulations by means of
the CHARMM program (23), using a setup similar to that
described for the modeling of the closely-related oxytocin
receptor (24). Harmonic restraints of 2.5 kcal/mol/Å2 on the
receptor backbone atoms except for the second extracellular
loop and the experimentally identified disulfide-bonded N-ter-
minal domain (25) were applied to allow small conformational
changes of the receptor during theMDsimulationswithout loss
of the overall receptor topology (26). Minimizations were car-
ried out by using 1500 steps of steepest descent followed by a
conjugate gradient minimization, until the root-mean-square
gradients was less than 0.001 kcal/mol/Å. A distance-depend-
ent dielectric term (  4r) and a 12 Å non-bonded cut-off
distance were chosen. The systemwas heated to 300 Kwith 5 K
rise, every 100 steps per 6000 steps, by randomly assigning
velocities from the Gaussian distribution. After heating, the
system was allowed to equilibrate for 34 ps. Finally, a produc-
tion phase was carried out involving a 100 ps simulation using
anNVTensemble at 300K, with a time steps of 1 fs. Themodels
wereminimized as above and used for the comparative analysis.
Materials—GnRH I and GnRH II were purchased from
Sigma and Bachem. [His5,D-Tyr6]GnRH, [His5]GnRH,
[Trp7]GnRH, [Tyr8]GnRH, chicken GnRH I ([Gln8]GnRH),
frog GnRH ([Trp8]GnRH), and seabream GnRH ([Ser8]GnRH)
were synthesized in our laboratory as previously described (10).
IN3, (2S)-2-[5-[2-(2-azabicyclo[2.2.2]oct-2-yl)-1,1-dimethyl-
2-oxoethyl]-2-(3,5-dimethylphenyl)-1H-indol-3-yl]-N-(2-
pyridin-4-ylethyl) propan-1-amine was obtained fromMERCK
(10).
Data Analysis—Binding curves were fitted to the Hill equa-
tion or to the one-site model using Sigmaplot 9.0 (SPSS) yield-
ing an IC50 value. The receptor expression levels were calcu-
lated as percentage of the wild-type control included in each
transfection. PhI dose-response curves were fitted to a four-
parameter logistic function, yielding a basal activity, a maxi-
mum response (Emax), an EC50 value and a slope factor.
RESULTS
Mutation of Asn7.45 to Ala Induces a Receptor Conforma-
tional Instability That Is Rescued by a Membrane-permeant
Non-peptide GnRH Antagonist—Mutation of Asn7.45 to Ala
completely abolished receptor expression on cell surfaces when
transiently transfected into COS-7 cells, as measured by ligand
binding assays with a hydrophilic peptide agonist 125I-[His5,D-
Tyr6]GnRH on intact cells (Fig. 2A, inset). Themutant receptor
also gave undetectable PhI responses.3 To investigate if a cell
membrane-permeant non-peptide GnRH antagonist, IN3,
could rescue the mutant receptor by chaperoning it to the cell
surface, the wild-type and mutant receptor transfected COS-7
cells were preincubated with 1 M IN3 for 48 h. After washing
out the IN3 as described previously (10), the expression level of
the mutant receptor was measured by radioligand binding giv-
ing 40% of the wild-type level (Fig. 2A, inset). The action of the
chaperone ligand IN3 on receptor expression was observed not
only in the mutant GnRH receptor but also in the wild-type
receptor (Fig. 2A, inset). Pretreatment of the receptor-trans-
fected COS-7 cells with IN3 had no effect on GnRH ligand
binding affinity in the wild-type receptor after washout (Fig.
2A). This result suggests that the membrane-permeant non-
peptide GnRH antagonist IN3 can bind with the newly synthe-
sized receptor inside of cells, and alter receptor conformations
from an unstable to a more stable state.
Effect ofMutation of Asn7.45 to Ala on Receptor Binding Affin-
ity of GnRH Analogues—The mutation N7.45A had little effect
on binding affinity of GnRH I (Fig. 2B) and [His5,D-Tyr6]GnRH,
which we conventionally use as a radioligand (Fig. 2A), but
increased affinity of the mutant receptor for GnRH II by 8-fold,
as compared with the affinity of the wild-type receptor for
GnRH II (Fig. 2B and Table 1). There are three amino acid
differences between GnRH I and GnRH II in which Tyr5, Leu7,
and Arg8 of GnRH I are replaced by His5, Trp7, and Tyr8 in
GnRH II (Fig. 1A). We examined the effect of mutation of
Asn7.45 to Ala on the binding affinity of GnRH I analogues with
single amino acid substitutions (His5, Trp7, or Tyr8). Themuta-
tion N7.45A had no significant effect on the receptor binding
affinity for [His5]GnRH and [Trp7]GnRH, but increased recep-
tor binding affinity for [Tyr8]GnRH by 14-fold (Fig. 2C and
Table 1).
3 Z. L. Lu, unpublished observation.
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The binding of GnRH I, which contains Arg8, to the wild-
type human GnRH receptor was characterized by one-site
binding isotherms (nH  0.86) with an IC50 at 2.6 nM. The
binding affinities of the wild-type human GnRH receptor for
GnRHs from other species which only have one amino acid
difference in position 8, including chicken GnRH I
([Gln8]GnRH), frog GnRH ([Trp8]GnRH), and seabream
GnRH ([Ser8]GnRH) (Fig. 1A) were much lower than GnRH I
with IC50 values at 80 nM, 111nM, and 684nM (Fig. 2D andTable
1). Interestingly, mutation of Asn7.45 to Ala also increased the
mutant receptor affinity for chicken GnRH I ([Gln8]GnRH),
frog GnRH ([Trp8]GnRH), and seabream GnRH ([Ser8]GnRH)
by 10-fold as was seen for [Tyr8]GnRH (Fig. 2D and Table 1).
Effect of Mutation of Asn7.45 to Ala on the GnRH Ligand-
elicited PhI Turnover—When the N7.45A mutant receptor
expression was rescued, GnRHs were able to elicit a functional
response. Interestingly, GnRH I and GnRH II elicited a maxi-
mum phosphoinositide (PhI) response in the N7.45A mutant
receptor of 110–122% that of the wild-type receptor (Fig. 3A)
even though its expression was only 40% of the wild-type level,
suggesting increased signaling efficacy. In parallel with the
increased GnRH II binding affinity, the mutant receptor was
also more potent in eliciting PhI response, leading to a 3-fold
decrease in the EC50 value as compared with the wild-type
receptor (Fig. 3A and Table 2).
Activation of GnRH receptors from different species by their
cognate ligands can selectively couple to different members of
the G protein family such as Gq/11, Gs, and Gi/o. The human
GnRH receptor preferentially couples to Gq/11, although cou-
pling toGs andGi/o was reported in certain cell types (6). GnRH
I elicits a robust PhI response fromCOS-7 cells transfectedwith
the human GnRH receptor, giving a maximum response five
times the basal activity and an EC50 value of 0.2 nM (Fig. 3, A
and B). Chicken GnRH I ([Gln8]GnRH), frog GnRH I
([Trp8]GnRH), and seabream GnRH I ([Ser8]GnRH) were able
to activate Gq/11-mediated PhI turnover in the human GnRH
receptor with increased EC50 values (Table 2). However, all of
them acted as partial agonists giving reduced Emax responses at
44–83% of that elicited by GnRH I (Fig. 3B and Table 2). Most
interestingly, all of them became full agonists in the N7.45A
mutant receptor, even though the expression is only 40% of the
wild-type, yielding Emax responses equal to or greater than that
elicited by GnRH I in the wild-type receptor with little or only a
small effect on the signaling potency (EC50 value) (Fig. 3B and
Table 2).
FIGURE 2. Competitive binding of GnRH analogues at wild-type and N7.
45A mutant receptors. The wild-type and N7.45A mutant receptor trans-
fected COS-7 cells were preincubated with or without 1 M IN3 for 48 h. The
IN3 was washed off prior to binding assays. A, homologous binding of [His5,D-
Tyr6]GnRH, mutation of Asn7.45 to Ala led to an undetectable GnRH ligand
binding, which was rescued by IN3 preincubation of the transfected cells
(inset). There was no difference in the GnRH binding affinity between the IN3
pretreated and the untreated cells of wild-type receptors. F, wild-type; E,
wild-type with IN3 pretreatment; , N7.45A with IN3 pretreatment. B, com-
petitive binding of GnRH I (F and E) and GnRH II (f and ) at the wild-type
and N7.45A mutant receptors. C, competitive binding of GnRH I analogues
with single amino acid substitution of GnRH II in GnRH I at position 5, 7, or 8 at
the wild-type and N7.45A mutant receptors, [His5]GnRH (F and E);
[Trp7]GnRH (f and ); [Tyr8]GnRH ( and ). D, binding of GnRHs from
different species with Arg8-substitution. GnRH I (F and E); chicken GnRH I
([Gln8]GnRH) (f and ); frog GnRH ([Trp8]GnRH) ( and ); seabream GnRH
([Ser8]GnRH) (Œ and ‚). - - - - - -, wild-type; - - - -, N7.45A. Arrows indicate shift
in affinity of the mutant receptor for Arg8-substituted GnRHs at the N7.45A
mutant receptor.
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Identification of the Asn7.45-interacting Residue in the
Human GnRH Receptor—In the refined GnRH receptor
homologymodel in the inactive state, built on the crystal struc-
ture of bovine rhodopsin in the dark state (14), Asn7.45 faces
toward Cys6.47. Mutation of Cys6.47 to Ala or to Tyr (a naturally
occurring mutant in human infertility) led to undetectable
ligand binding and PhI responses. This phenotype is similar to
that of N7.45A. Themutant receptor expression of C6.47A and
C6.47Y at the cell surface was rescued by IN3 pretreatment,
giving 38 and 18% that of the wild-type (Fig. 4B, inset). As with
N7.45A, the mutations C6.47A and C6.47Y led to 3–5-fold
increases in GnRH II binding affinity as compared with the
wild-type receptor (Fig. 4A andTable 1). Bothmutant receptors
showed an increased signaling efficacy for GnRH II, yielding
Emax responses greater than that of the wild-type with
decreased EC50 values (Fig. 4B and Table 2).
DISCUSSION
GPCRs for peptide ligands are frequently present as a variety
of subtypes encoded by distinct genes. The presence ofmultiple
isoforms of peptide ligands which preferentially bind to the
cognate receptor subtypes implies co-evolution of peptide
ligands and receptors. The conventional wisdom in regard to
ligand binding and effector coupling selectivity is that receptor
subtypes incorporate changes in binding site residues for ligand
selectivity and changes in intracellular domains for coupling
selectivity. Our studies here have shown an important role of
receptor conformations in determining ligand binding selectiv-
ity and signaling efficacy in the human GnRH receptor.
Mutation of Asn7.45 to Ala led to
undetectable ligand binding andPhI
responses, which were rescued by a
membrane-permeant, non-peptide
GnRH antagonist, IN3 (Fig. 2, A
and B), suggesting that the side
chain of Asn7.45 makes intramo-
lecular interactions which are
important for receptor folding.
Disruption of the intramolecular
interactions appears to cause
receptor conformational changes
which can be modulated by the
pharmacological chaperon, facili-
tating mutant receptor trafficking
to the cell surface and indicating a
ligand influence on receptor con-
formations. The pharmacological chaperoning effects of IN3
have been extensively studied by Conn and co-workers (27–30)
in which IN3 has been shown to increase protein expression
levels of mutant receptors on the cell membranes and to facili-
tate trafficking of the misfolded mutant receptors from endo-
plasmic reticulum (ER) to the cell surfaces. Membrane-per-
meant antagonists have also been extensively used to rescue
receptor expression of structurally unstable mutants on cell
surfaces in other GPCRs (31–39).
ThemutationN7.45A had no or only amarginal effect on the
receptor binding affinity for GnRH I, [His5]GnRH and
[Trp7]GnRH, but markedly increased receptor binding affinity
for GnRH II and [Tyr8]GnRH (Fig. 2, B and C). This is consist-
ent with our previous suggestion that Tyr8 in GnRH II is
involved in receptor conformational selection (10). An alloste-
ric effect of Asn7.45 mutation on ligand binding affinity was also
observed in the M1 muscarinic acetylcholine receptor
(mAChR), which increased receptor binding affinity not only
for agonists, but also for certain antagonists (16).
The conformation of the wild-type human GnRH receptor
has apparently evolved for high affinity binding to mamma-
lian GnRH I, which contains Arg8 and therefore has a lower
affinity for the second endogenous ligand, GnRH II, possess-
ing Tyr8 (Fig. 2B) and GnRHs from other species, which only
have one amino acid difference in position 8, including
chicken GnRH I ([Gln8]GnRH), frog GnRH ([Trp8]GnRH),
and seabream GnRH ([Ser8]GnRH) (Fig. 2D). Most interest-
ingly, mutation of Asn7.45 to Ala also markedly increased the
FIGURE 3. GnRHs elicited PhI responses at wild-type and N7. 45A mutant receptors. A, GnRH I (F and E)
and GnRH II (f and ) stimulated PhI responses. B, PhI responses elicited by GnRHs from other species with
Arg8-substitution, F, GnRH I; f and , chicken GnRH I ([Gln8]GnRH);  and , frog GnRH ([Trp8]GnRH); Œ and
‚, seabream GnRH ([Ser8]GnRH). - - - - - -, wild-type; - - - -, N7.45A.
TABLE 1
The binding of GnRH analogues to wild-type and mutant human GnRH receptors
Ligand binding were conducted as described under “Experimental Procedures.” Values are mean  S.E. from three or more independent experiments. The competing
radioligand was 125I-His5,D-Tyr6GnRH.
Binding affinity (IC50)
GnRH I GnRH II Tyr8GnRH Gln8GnRH Trp8GnRH Ser8GnRH
nM nM nM nM nM nM
Wild-type 2.6  0.2 29  2 222  13 80  6 111  8 684  43
Wild-type  IN3a 2.5  0.3 28  3 211  23 94  10 107  5 621  30
N7.45Aa 1.5  0.2 3.7  0.5 16  3 8.1  2.2 12  1 48  3
C6.47Aa 3.2  0.1 9.6  0.7
C6.47Ya 2.8  0.3 5.2  0.6
a With IN3 pretreatment.
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mutant receptor affinity for chicken GnRH I, frog GnRH,
and seabream GnRH, as that of GnRH II and [Tyr8]GnRH.
These results indicate an important role of receptor confor-
mations in determining ligand binding selectivity developed
during evolution, which can be manipulated by mutation-
induced receptor conformational changes without alteration
of the side chains of the ligand binding sites. These results
support our proposal of co-evolution of ligand-receptor con-
formations. A single amino acid in position 8 of GnRHs acts
as a structural determinant for receptor binding selectivity.
We propose that ligands might exert a directive role in the
evolution of receptor structure including primary and terti-
ary structures accounting for the origin of receptor specific-
ity and diversity, consistent with the proposal that neu-
ropeptide genes arose before the corresponding receptor
genes and that their receptors might have evolved as targets
for extant peptide ligands (40).
ChickenGnRH I ([Gln8]GnRH), frog GnRH I ([Trp8]GnRH),
and seabreamGnRH I ([Ser8]GnRH), whose side chains at posi-
tion 8 appear to be able tomakeH-bonds with receptor contact
residues, act as partial agonists in the wild-type human GnRH
receptor (Fig. 3B). Most interestingly, all of them became full
agonists in the N7.45A mutant receptor. We propose that
GnRHs from different species that differ by only one amino
acid in position 8 can selectively stabilize different receptor
active conformations with different signaling efficacy. We
envisage this occurs through common and differential
receptor intramolecular and receptor-ligand intermolecular
interactions. Arg8 of GnRH I (Fig. 1B) has been shown to
interact with Asp7.32 (Fig. 1C), but
this is not the case for Tyr8 of
GnRH II (41). There is increasing
evidence that different ligands can
induce different receptor confor-
mations with different signaling
capability (42, 43) and in such a
way, some partial agonists and
even some inverse agonists
become full agonists in activating
different signaling pathways (44–
46). Interestingly, agonists differ-
ing by only a single hydroxyl group
can lead to differential signaling in
a Drosophila octopamine/tyra-
mine receptor (47). Apparently,
high affinity ligand binding can be achieved not only by opti-
mization of ligand binding sites, but also by inducing ligand-
specific receptor intramolecular contacts that stabilize each
binding partner (48), hence creating a ligand-specific recep-
tor conformation which can be facilitated by weakening the
receptor constraint networks. Recent studies have clearly
shown that partial agonists stabilize a receptor conformation
differing from that of full agonists in other GPCRs (49–51).
The marked loss of receptor binding (undetectable) without
loss of binding affinity (determined after rescue with IN3) and
the increases of signaling efficacy of the mutation of Asn7.45 to
Ala indicate that the side chain of Asn7.45makes intramolecular
interactions, forming part of the receptor constraint network.
To identify the residues interacting with Asn7.45, we mutated
residues (Glu2.53, Ser3.35, Cys6.47, Trp6.48 (52), Thr6.49, and
Asp7.49), which potentially interact with Asn7.45, predicted by
molecular modeling. Only Cys6.47 mutants gave a similar phe-
notype of unchanged binding affinity for GnRH I but increased
binding affinity for GnRH II (Fig. 4) to the N7.45Amutant. Our
molecular modeling has shown that the side chain of Asn7.45
can make an intramolecular interaction with Cys6.47 in the
inactive state of the receptor (Fig. 5, A and B). The model was
validated by accommodation of all experimentally identified
receptor intramolecular interactions (10, 53–56) and the exper-
imentally identified GnRH ligand-receptor intermolecular
interactions (Fig. 1C) (6, 10). We therefore propose that the
residues of Asn7.45 and Cys7.49 form part of the intramolecular
constraint network involved in the stabilization of different
FIGURE 4. Binding and PhI assays of GnRH II at wild-type, C6.47A and C6.47Y mutant receptors.
A, competitive binding showing an increased affinity of the mutant receptors for GnRH II. B, PhI assay of GnRH
II. F, wild-type; f, C6.47A; , C6.47Y. Inset shows the mutant receptor expressions relative to the wild-type level.
TABLE 2
Receptor expression and functional responses of the wild-type and mutant GnRH receptors
Measurements of the receptor expression levels on cell surfaces (Bmax) using radioligand binding assay onwhole cells, and PhI responses were conducted as described under
“Experimental Procedures.” The Bmax and the maximum PhI responses (Emax) were expressed relative to a wild-type control in each transfection. Values are mean  S.E.
from three or more independent experiments.
PhI responses
Bmax
GnRH I GnRH II Gln8GnRH Trp8GnRH Ser8GnRH
EC50 Emax EC50 Emax EC50 Emax EC50 Emax EC50 Emax
% nM % nM % nM % nM % nM %
Wild-type 100 0.2  0.1 100 6.9  1.4 100 10  2 83  9 4.6  0.6 53  6 48  6 44  5
N7.45Aa 40  4 0.2  0.1 110  13 2.2  0.4 122  7 5.1  1.7 132  12 8.5  0.3 104  5 50  4 102  4
C6.47Aa 38  3 0.1  0.1 122  8 1.8  0.9 131  9
C6.47Ya 18  3 0.2  0.1 102  7 2.2  1.2 115  6
a With IN3 pretreatment.
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receptor conformations which have preferential engagement
with partial and full agonists. Partial agonists may only break
part of the intramolecular constraint network. Mutations of
Cys6.47 in the 2 adrenergic receptor (57) and Asn7.45 in the
histamine H1 receptor (58) lead to constitutive activation of
the receptors, indicating an important role of this residue in the
receptor conformational switch. We have built a model of the
human GnRH receptor in an active conformational state using
the crystal structure of a photoactivated deprotonated interme-
diate of bovine rhodopsin (15) as a template. In the model, the
intramolecular interactions between Cys6.47 and Asn7.45, and
between Met3.43 and Phe6.40, which we identified previously
(10), are disrupted due to amotion of themiddle section of TM
3, as seen as a disorder of the helix (Fig. 5C), and a slight out-
wardmovement of TM6 followed by a small clockwise rotation
(viewed from the extracellular surface) of the intramolecular
segment by using Pro6.50 as a hinge
(59) (Fig. 5C). Consistent with the
mutagenesis results, our molecu-
lar modeling also indicates that
these intramolecular interactions
are involved in receptor confor-
mational transition. Interestingly,
no constitutive activity in any
mutations of the human GnRH
receptor was observed, unlike the
2 (57) and H1 (58) receptors. This
indicates that weakening the
intramolecular interactions in the
human GnRH receptor is not suf-
ficient to obtain an active confor-
mation, but rather modifies recep-
tor conformational states which
are, at least, allosterically involved
in ligand binding selectivity and
signaling efficacy. We propose
that GnRH ligand-induction of
new receptor intra- and intermo-
lecular interactions might be a
fundamental component for
GnRH receptor activation, rather
than a ligand-induced disruption
of the receptor intramolecular
constraint networks, which we
proposed as a mechanism of the
M1 mAChR activation (16). This
may provide an explanation for
the distinct pharmacological pro-
files of GnRH analogues in stimu-
lating pituitary gonadotropin and
inhibiting cancer cell proliferation
(6). Of the endogenous ligands
GnRH I is more potent in stimu-
lating gonadotropins (6) but
GnRH II has greater antiprolifera-
tive potency (60). Interestingly,
the presence of Asp7.49, located
one helix below Asn7.45 in the
GnRH receptor because of a reciprocal exchange of the
highly conserved Asp2.50-Asn7.49 pair in other GPCRs pre-
vents the GnRH receptor from coupling to phospholiphase D
via small G proteins (61), supporting our conclusion that
residues within this region play an important role in the
stabilization of different receptor conformations, and
account for ligand binding and signaling selectivity.
In conclusion, our molecular modeling and mutagenesis
studies have indicated that the side chains of the highly con-
served Asn7.45 and Cys6.47 make intramolecular contacts in the
inactive state (Fig. 5, A and B) which form part of the receptor
allosteric network, coupling to specific structural elements of
theGnRH analogues. Thismay underlie different receptor acti-
vation mechanisms, creating different receptor active confor-
mations with potential ligand selective signaling described for
these ligands. The identification of structural elements for
FIGURE 5. Homology models of human GnRH receptor in inactive and active conformations. A, stereo view
of the 7-TM domains of the human GnRH receptor. The model was derived from the crystal structure of bovine
rhodopsin in the inactive state (see “Experimental Procedures”). The model reveals the hydrogen bond inter-
action between Cys6.47 and Asn7.45. The previously experimentally identified hydrogen bonds (green dash lines)
between Asp2.61 and Lys3.32 (56), between Asp3.49 and Arg3.50 (55), and between Asn1.50, Asn2.50, and Asp7.49
(53, 54) and the hydrophobic interactions between Met3.43 and Phe6.40 (and surrounding residues Met5.54,
Phe6.44, and Ile7.32) (10) among the 7-TM domains, which validate our GnRH receptor model, were also shown.
The GnRH receptor binding residues Asp2.61, Trp2.64, Asn2.65, Lys3.32, Asn5.39, Tyr6.58,and Asp7.32 (see Fig. 1C) are
also included. B, intramolecular interactions between Cys6.47 and Asn7.45. The side chains of Cys6.47 and Asn7.45
form part of allosteric intramolecular communication networks that confer GnRH ligand binding selectivity
and signaling efficacy. Two previously identified residues (Met3.43 and Phe6.40) whose mutations have no effect
on GnRH I binding affinity, but specifically increase affinity for GnRH II and [Tyr8]GnRH are also shown (10). C, a
GnRH receptor model in the active conformation, in which there are no intramolecular interactions between
Cys6.47 and Asn7.45 and between Met3.43 and Phe6.40. TM 3 is shown in orange, TM 6 in blue, and TM 7 in olive
green in B and C.
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ligand and receptor conformational selection could have
implications for the development of novel ligands that selec-
tively activate one signaling pathway, bypassing others, and
hence with improved pharmacological specificity and pro-
files. Our studies also support our proposal that ligand bind-
ing selectivity is determined not only by ligand binding res-
idues, but also by receptor conformation. The conformation
of GPCRs has been specialized during evolution by forming a
complex receptor intramolecular interaction network. This
accounts for selective binding of the cognate ligands and G
proteins. The highly conserved amino acids appear to form
part of the allosteric network which might serve as con-
straints for receptor inactive states. Mutation of a residue
within the allosteric network can alter receptor binding
selectivity of ligands and G proteins through subtle receptor
conformational changes, which might be one of the mecha-
nisms of development of ligand binding and signaling selec-
tivity and diversity of GPCRs during evolution.
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